Metamizol Noridem (Metamizole Sodium Monohydrate)

The precise mechanism of Metamizole is not fully understood. It is thought to inhibit prostaglandin synthesis, possibly through cyclooxygenase blockade, and to act on central pain pathways, thereby decreasing nociceptive transmission and lowering the hypothalamic temperature set‑point.

Dosing is individualized and must be determined by the prescribing clinician based on the patient’s condition, weight, route of administration, and clinical response. No fixed regimen is provided here; the prescriber will set the appropriate dose.

Safety data for Metamizole in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and only under the guidance of a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Metamizole belongs to the pyrazolone class, offering analgesic and antipyretic effects similar to NSAIDs but with a distinct safety profile. Unlike opioids, it does not act on opioid receptors, and compared with traditional NSAIDs, it may have a lower incidence of gastrointestinal irritation but carries a risk of agranulocytosis.

Store Metamizol Noridem at temperatures below 25 °C. Keep the vials in their original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly sealed to maintain sterility.

Metamizol Noridem is supplied as a sterile injectable solution and must be administered by a qualified healthcare professional via intramuscular or intravenous injection, following aseptic technique and appropriate dosing guidelines.

The most serious adverse events include agranulocytosis, which can lead to severe infection, and life‑threatening hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome. Immediate medical attention is required if signs of these conditions appear.

Metamizol is contraindicated in individuals with known hypersensitivity to pyrazolones, a history of severe blood dyscrasias (e.g., agranulocytosis), or those with uncontrolled severe liver disease. It should also be avoided in patients where alternative therapies are safer, as determined by the treating physician.